1. Gefitinib provides similar effectiveness and improved safety than erlotinib for east Asian populations with advanced non–small cell lung cancer: a meta-analysis
   Wenxiong Zhang et al, 2018, BMC Cancer CrossRef
2. Prognostic value of serum cytokeratin 19 fragments (Cyfra 21-1) in patients with non-small cell lung cancer
   Youtao Xu et al, 2015, Scientific Reports CrossRef
3. Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib
   Evelyn M. McKeegan et al, 2015, Lung Cancer CrossRef
4. Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study
   Akira Ono et al, 2013, BMC Cancer CrossRef
5. Tumour biomarkers: association with heart failure outcomes
   C. Shi et al, 2020, Journal of Internal Medicine CrossRef
6. Prognostic value of baseline carcinoembryonic antigen and cytokeratin 19 fragment levels in advanced non-small cell lung cancer
   Ae Rin Baek et al, 2018, Cancer Biomarkers CrossRef
7. Response to first-line erlotinib in a false EGFR mutation-negative patient with non-small-cell lung cancer: Make no assumptions
   Caixia Deng et al, 2018, Open Journal of Cell and Protein Science CrossRef
8. EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment
   Dan Que et al, 2016, Cancer Biology & Therapy CrossRef
9. History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer
   Haruhiko Nakamura et al, 2017, Surgery Today CrossRef
10. Prognostic assessment of tumor markers in lung carcinomas
    Fernanda Bes-Scartezini et al, 2022, Revista da Associação Médica Brasileira CrossRef
11. Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer
    Mingzhong Sun et al, 2016, Disease Markers CrossRef
12. Nomogram for predicting recurrence and metastasis of stage IA lung adenocarcinoma treated by videoassisted thoracoscopic lobectomy
    Zhixin Huang et al, 2022, Asian Journal of Surgery CrossRef
13. Associations Between Epidermal Growth Factor Receptor Gene Mutation and Serum Tumor Markers in Advanced Lung Adenocarcinomas: A Retrospective Study
    Ying-qiu Pan et al, 2014, Chinese Medical Sciences Journal CrossRef
14. Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma
    Bo Jin et al, 2014, Acta Pharmacologica Sinica CrossRef
15. Retraction: Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Yonsei Med J 2012;53:931-9.
    Minkyu Jung et al, 2013, Yonsei Medical Journal CrossRef
16. Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of cancer biological behaviour regulated by EGFR mutation
    JianYong Zou et al, 2014, Journal of International Medical Research CrossRef
17. Is There a Relationship Between Serum Carcinoembryonic Antigen Level and Epidermal Growth Factor Receptor Mutations in Resected Lung Adenocarcinomas ?
    Masaki Tomita et al, 2013, Annals of Cancer Research and Therapy CrossRef
18. Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations
    Juanjuan Dong et al, 2021, Cancer Management and Research CrossRef
19. Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis
    Zuyao Yang et al, 2017, International Journal of Cancer CrossRef
20. CEA serum level as early predictive marker of outcome during EGFR-TKI therapy in advanced NSCLC patients
    Francesco Facchinetti et al, 2015, Tumor Biology CrossRef
21. Prognostic Value of Pretreatment Serum Carcinoembryonic Antigen Level in 1130 Patients With Non-small Cell Lung Cancer
    Fengzhou Li et al, 2023, American Journal of Clinical Oncology CrossRef
22. Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer
    Wenxiong Zhang et al, 2018, Medicine CrossRef
23. Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis
    Zipu Yu et al, 2017, Oncotarget CrossRef
24. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008–2022 update
    Inga Trulson et al, 2024, Tumor Biology CrossRef
25. Prognostic value of serum CYFRA21‐1 and CEA for non‐small‐cell lung cancer
    Zhi‐Hui Zhang et al, 2015, Cancer Medicine CrossRef
26. Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
    Shaohua Cui et al, 2017, Tumor Biology CrossRef
27. Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    Yu-Mu Chen et al, 2015, Medicine CrossRef